

innate pharma

# Q1 2023 Business Update

10 MAY 2023

EURONEXT : IPH.PA  NASDAQ : IPHA

# Disclaimer on Forward-Looking Information and Risk Factors

## This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company's actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the Autorité des Marchés Financiers ("AMF"), available on the AMF website (www.amf-france.org) or on the Company's website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company's estimates based on such sources.

This presentation discusses product candidates that are under clinical development, and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

innate pharma

# Speakers on Today's Call



**Mondher Mahjoubi**
MD

Chief Executive Officer

Chairman of the Executive Board



**Joyson Karakunnel**
MD, MSc, FACP

Chief Medical Officer



**Yannis Morel**
PhD

Head of Business Development and Product Portfolio Strategy



**Frédéric Lombard**
MBA
(Q&A)

Chief Financial Officer

innate pharma

# Scientific innovation drives our strategy







**Our ambition –**
leverage our scientific know-how in innate immunity and antibody engineering to develop cancer drugs that improve the lives of patients.

Drive near-term value with lacutamab

Advance our innovative pipeline

Build a sustainable business through partnerships

innate pharma

# Our robust pipeline of proprietary & partnered assets

| | Program | Target | Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Upcoming Milestone |
|---|---|---|---|---|---|---|---|---|
| Proprietary | Lacutamab | KIR3DL2 | Sezary syndrome | | TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) | | | Final data H2 2023 |
| | | | Mycosis Fungoides | | TELLOMAK | | | Final data H2 2023 |
| | | | PTCL (combo with GemOx) | | KILT | | | IST with LYSA |
| | | | PTCL (mono) | | PHASE 1b | | | Preliminary data H2 2023 |
| | IPH5301 | CD73 | Cancer (solid tumors) | | CHANCES | | | IST with IPC |
| | IPH6501<br>Others | CD20<br>Targets undisclosed ANKET | | | Pre-clinical | | | IPH6501 IND in 2023 |
| | IPH4501<br>IPH43 | ADC, target undisclosed<br>ADC, MICA/B | | | Pre-clinical | | | |
| Partnered | Monalizumab AstraZeneca | NKG2A | Unresectable Stg III NSCLC | | PACIFIC-9 | | | Data readout > 2024 |
| | | | Neoadjuvant NSCLC | | NeoCOAST-2 | | | Data readout > 2024 |
| | IPH5201 AstraZeneca | CD39 | Neoadjuvant NSCLC | | MATISSE | | | Phase 2 started |
| | IPH6101 / SAR'579<br>IPH6401 / SAR'514<br>IPH62<br>2 options sanofi | CD123<br>BCMA<br>B7-H3<br>Targets undisclosed ANKET | R/R AML, B-ALL, HR-MDS | | PHASE 1<br>Research | | | |
| | Other Takeda | ADC, target undisclosed | Celiac disease | | Pre-clinical | | | |

ADC: antibody drug conjugate; GemOx: gemcitabine and oxaliplatin; PTCL: Peripheral T Cell Lymphoma; NSCLC: Non-small cell lung cancer; AML: Acute Myeloid Leukemia; IST: investigator-sponsored study; IND: Investigational new drug;

# Lacutamab | Development strategy

A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment.

## Cutaneous T cell lymphoma

### Sézary syndrome

**80-200** patients
>90% KIR3DL2 expression

### Mycosis fungoides (MF)

**2,200-4,400** patients
~50% KIR3DL2 expression

TELLOMAK

## Phase 2 Trial

Sézary syndrome

Cohort 1 (N~60)

Minimum of 2 prior therapies, including mogamulizumab

Mycosis fungoides

3 cohorts (N~100)

| Cohort 2 | Cohort 3 | Cohort 4 All comers |
|---|---|---|
| KIR3DL2 + | KIR3DL2 - | KIR3DL2 +/- |

At least 2 prior systemic therapies

Sézary syndrome
Phase 2
Final data H2 2023

Mycosis fungoides
Phase 2
Final data H2 2023

## Peripheral T cell lymphoma

**~18,000** patients
~50% KIR3DL2 expression

## Phase 1b/2 Trials

### Phase 1b trial

**monotherapy**

### KILT Phase 2 trial

**combination with GEMOX** chemotherapy (gemcitabine in combination with oxaliplatin) versus GEMOX alone

Preliminary data expected in H2 2023

# Lacutamab | Preliminary efficacy results in CTCL support further development

Final data from TELLOMAK Phase 2 trial in H2 2023

## Sézary syndrome

### Cohort 1 (N~60)

Minimum of 2 prior therapies, including mogamulizumab

**6** median lines of prior therapy

**10.9** months medial follow up




Best **global** response

**21.6%**



- 8 patients achieved Global Response (GR)
- Median time to GR: 4 months (range: 1.0-6.5)
- Median DoR is 10.8 months (95% CI: 6.2-12.3

Best **skin** response

**35.1%**



- 13 patients achieved a Skin Response (SR)
- Median time to SR: 2.8 months (range: 0.9-10.2)

Best **blood** response

**37.8%**



- 14 patients achieved a Blood Response (BR)
- Medan time to BR: 1.0 month (range:1.0-6.5)

Results from an interim analysis presented at ASH 2022

## Mycosis fungoides

### 3 Cohorts (N~100)

At least 2 prior systemic therapies

### Cohort 2 - MF KIR3DL2+

- Global ORR **28.6%** (including 2 CR and 4 PR)
- Skin response **57.1%**
- Confirmed favorable tolerance profile, including in the skin




EORTC European Organisation for Research and Treatment of Cancer
*The future of cancer therapy*

Phase 2 data presented at EORTC 2022

CTCL: cutaneous T cell lymphoma

# Monalizumab development in progress of Phases 2 and 3 trials

Covering early stages of lung cancer

*Stages of the disease*

Upcoming presentation

**NSCLC Stages I - III resectable**

NeoCOAST*

30% major pathological response
vs. 11% durvalumab.

Data presented: 2022
AACR American Association for Cancer Research
ESMO congress

NeoCOAST-2*
PHASE 2
Patients with Stage II to IIIB NSCLC
Monalizumab + durvalumab + chemotherapy

210 patients (multiple arms)

2023 ASCO ANNUAL MEETING
Abstract : TPS8604
Trial in Progress

**NSCLC Stage III unresectable**

COAST*

~ 60% reduction in the risk of disease progression vs. durvalumab.

~ 15 months average duration of progression-free survival.

Data presented: 2021
ESMO congress

Posted in: April 2022
Journal of Clinical Oncology

PACIFIC-9*
PHASE 3
Patients with Stage III unresectable NSCLC
Monalizumab + durvalumab

999 patients (3 arms)

2023 ASCO ANNUAL MEETING
Abstract : TPS8610
Trial in Progress

* Study run by AstraZeneca

innate pharma

ANKET®
Antibody-based NK cell Engager Therapeutics

# Proprietary NK cell engager platform

Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46.

Provides proliferation and activation signals targeted to NK cells.

Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models.







**A versatile, fit-for-purpose technology** that is creating **an entirely new class** of tri- and tetra-specific molecules to induce synthetic immunity against cancer.

# ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells

## Growing clinical pipeline

| | | |
|---|---|---|
| IPH6101 / SAR'579 (CD123) | sanofi | Phase 1 |
| IPH6401 / SAR'514 (BCMA) | sanofi | Pre-IND |
| IPH6501 (CD20) | innate | Pre-IND |
| IPH62 (B7-H3) | sanofi | Research |
| 2 options | sanofi | Research |
| Multiple Targets | innate | Research |

ANKET®
Antibody-based NK cell Engager Therapeutics

## Innate Pharma differentiated MoA

Nature Biotechnology
January 2023




Cell reports medicine
October 2022




ASH 2022 abstract: 4486, 3329, Antibody-Based NK Cell Engager Therapeutics

# IPH6101/SAR'579 Oral presentation at ASCO 2023

sanofi

IPH6101/SAR'579 is the first NKp46/CD16-based NK cell engager using Innate's proprietary multispecific antibody format ANKET®

## Preclinical rationale

IPH6101 induced AML cancer cell killing and is not affected by CD64 expression

- Anti-tumor **activity** in **pre-clinical** models
- **Supporting PK/PD** and safety data in non-human primate studies
- **Favorably compares to T-cell engager** in cytokine release assays




## Abstract selected for an oral presentation at the 2023 ASCO Annual Congress

2023 ASCO ANNUAL MEETING

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia

Abstract # 7005 - First Author Anthony Stein
Session Type Oral Abstract Session
6/2/2023, 1:00 PM - 4:00 PM

**Phase 1 Trial underway in AML**

innate pharma

ANKET®

sanofi

# Strategic partnership between Sanofi and Innate

Three molecules licensed to Sanofi plus two undisclosed targets under options

**Ongoing programs**

**IPH6101/SAR'579**
ANKET®
CD123
Phase 1 in AML

**IPH6401/SAR'514**
ANKET® x CROSSODILE® platform
BCMA
Progression towards IND

**IPH62**
ANKET®
B7-H3
Research

**OPTION**
ANKET®
2 undisclosed targets

**Payments received**

€14m

€25m upfront

2022 expansion

**Total amount of agreement**

€1.75 Bn
+ Royalties on net sales

Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration

innate pharma

# Partnership between Takeda and Innate

Exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC)

**Ongoing programs**

ADC using a panel of selected antibodies developed by Innate

Undisclosed target
Preclinical stage – with a primary focus in Celiac disease

**Payment received**

$5m upfront

**Total amount of agreement**

$415m
+ Royalties on net sales

Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies for ADC application



innate pharma

# Upcoming catalysts

Delivering across our strategic objectives

## 2023

- IPH6101 / SAR'579 ANKET ® (CD123) | Phase 1 (Sanofi) – ASCO 2023
- IPH6401 / SAR'514 ANKET® (BCMA) | IND progress (Sanofi)
- IPH6501 ANKET® (CD20) | IND Filing

- Lacutamab Phase 2 TELLOMAK | Final data SS & MF
- Lacutamab Phase 1b PTCL | preliminary data

## 2024+

- Monalizumab PACIFIC-9 | Phase 3 readout (AZ)
- Monalizumab NeoCOAST-2 | Phase 2 readout (AZ)
- IPH5201(CD39) MATISSE | Phase 2 readout (AZ)

- IPH6101 / SAR'579 ANKET® (CD123) | Next steps (Sanofi)
- IPH6401 / SAR'514 ANKET® (BCMA) | Next steps (Sanofi)
- IPH6501 ANKET® (CD20) | Phase 1 data
- IPH62 ANKET® (B7-H3) | Next Steps (Sanofi)
- 2 ANKET options | (Sanofi)

- Lacutamab CTCL | Next steps
- Lacutamab Phase 1b PTCL | Final data

innate pharma

# Abstracts to be presented by Innate's partners at the 2023 ASCO Annual Meeting

2023 ASCO ANNUAL MEETING
June 2-6 2023

## IPH6101 / SAR'579[1]

sanofi

Oral presentation[1]

### PHASE 1

Participants of at least 12 years of age with **Relapsed or Refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia**

**82 patients**

Preclinical data available:

- IPH6101 / SAR'579 kills AML **cells resistant to ADCC**
- IPH6101 / SAR'579 induce CD123-expressing **cell depletion** in NHP with minor cytokine release

ANKET

## PACIFIC-9

AstraZeneca

Trial in progress Poster[2]

### PHASE 3

Patients **with Stage III unresectable NSCLC**
Monalizumab + durvalumab

**999 patients** (3 arms)

Clinical data available (2021):

- COAST Phase 2 trial

## NEOCOAST-2

AstraZeneca

Trial in progress Poster[3]

### PHASE 2

Patients with **Stage II to IIIA NSCLC**
Monalizumab + durvalumab + chemotherapy

**210 patients** (multiple arms)

Clinical data available (2022):

- NeoCOAST Phase 2 trial

1 A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
2 Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9)
3 NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

# Key Takeaways

Create value for patients and shareholders

## Strategic Priorities

Early R&D focus to drive value through later stage partnerships

### Robust pipeline of Antibody engineering capabilities

- Advancing lacutamab
- Maximizing ANKET® platform
- Continuing to explore ADC

### Track record of strategic partnerships

AstraZeneca (monalizumab), Sanofi (IPH6101, IPH6401, IPH62, 2 options), Takeda (ADC)

### Strong cash position

- €135.0m* as of March 31, 2023 (not including $5m Takeda payment)
- Sufficient to fund operations into mid 2025

*Including short term investments (€17.1m) and non-current financial instruments (€35.6m)




innate pharma

# Thank you

www.innate-pharma.com
investors@innate-pharma.fr

EURONEXT : IPH.PA  NASDAQ : IPHA